Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
Primary Purpose
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
nanOss Bioactive Bone void filler
Interbody FCage
Sponsored by
About this trial
This is an interventional treatment trial for Degenerative Disc Disease focused on measuring PLF, lumbar fusion, bone graft, biologics
Eligibility Criteria
Inclusion Criteria:
The patient can be included in the study if all of the following criteria are met;
- is at least 18 years of age and skeletally mature
- must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc disease (DDD) at one or two adjacent levels from L2-S1 requiring a fusion
- must have completed a minimum of three months of unsuccessful conservative, non-operative care
- must have discogenic back pain with or without leg pain
- DDD must be confirmed by MRI or CT scans followed by discography (if necessary)
- must score at least 40 points on the Oswestry Disability Index
- must score at least a 4 on a 10 cm Visual Analog Scale for back pain
- must be able to comply with the protocol"s follow-up schedule
- must understand and sign the informed consent document
Exclusion Criteria:
The patient must not exhibit any of the following criteria;
- symptomatic at more than two levels
- previous fusion surgery at any lumbar level with or without instrumentation (prior discectomy, laminotomy, laminectomy or nucleolysis at the operative (involved) level > 6 months is permitted)
- more than 50% spondylolisthesis
- lumbar scoliosis greater than 11 degrees
- osteoporosis*, osteopenia, osteomalacia, Paget"s disease or metabolic bone disease.
- spinal tumors
- active arachnoiditis Pioneer Surgical Technology Confidential nanOss Bioactive Post Marketing Clinical Study: March 11, 2010 Page 8
- fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
- Impaired calcium metabolism
- active infection or surgical site infection
- rheumatoid arthritis or other autoimmune disease
- chronic steroid use (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing
- systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis
- morbid obesity defined as body mass index (BMI) >40 or a weight more than 100 lbs over ideal body weight
- smokers unless the patient agrees to quit at least 2 weeks prior to and for the duration of the study, confirmed by a carboxyhemoglobin test prior to surgery
- psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse
- active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years
- documented allergies to porcine collagen or titanium
- pregnancy, or interested in becoming pregnant in the next four years
- participation in another investigational study within 30 days *Osteoporosis will be assessed at the time of the preoperative evaluation based on the patient"s history, physical examination and review of the radiographic evaluations. All patients at risk for osteoporosis must obtain a DEXA scan of the spine and hip to determine if the patient has severe osteoporosis. The definition of a patient at risk used by the National Osteoporosis Foundation includes the following: i. Premature menopause (< 45 years) ii. Prolonged amenorrhea (> one year) iii. Maternal history of hip fracture iv. Primary hyperparathyroidism or hyperthyroidism v. Chronic renal failure vi. Previous fragility fractures, particularly of the hip, spine or wrist vii. Patients who have ever taken corticosteroids in doses >7.5 mg/day for one year or more. Patients will be excluded if their bone mineral density (BMD) in the spine or hip is more than 1.0 standard deviation (SD) below the mean of normal adults in the presence of one or more fragility fractures indicating severe osteoporosis. If severe osteoporosis is diagnosed, the patient must be excluded from the investigational study. If the patient has osteoporosis or osteopenia, they may be included in the study if he or she meets the rest of the inclusion and exclusion criteria.
Sites / Locations
- Tower Orthopaedics & Neurosurgical Spine Institute
- Scripps Memorial Hospital Neurosurgery
- Northwestern Medical Facility
- Advanced Center for Orthopedics
- St. Johns Spine and Pain Clinic
- Medical University of South Carolina Neurology
- Milwaukee Spinal Specialists
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
nanOss Bioactive Bone void filler
Arm Description
Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
Outcomes
Primary Outcome Measures
Spinal fusion
Bridging trabecular bone
Less than 3mm of translational motion
Less than 5mm of angular motion
Secondary Outcome Measures
Improvement in Oswestry Disability Index score
Improvement in VAS pain scores
Improvement in Quality of Life scores
Decrease in medication usage
Patient returning to work
Patient satisfaction (surgery satisfaction survey, e.g., very satisfied, satisfied, somewhat unsatisfied, or very unsatisfied with the surgery)
Full Information
NCT ID
NCT01452516
First Posted
September 2, 2011
Last Updated
November 7, 2016
Sponsor
Pioneer Surgical Technology, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01452516
Brief Title
Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
Official Title
A Prospective, Multi-Center, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Terminated
Why Stopped
Study was terminated due to slow accrual rate.
Study Start Date
July 2010 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pioneer Surgical Technology, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Spine fusion is one of the most common procedures performed in spinal surgery. Several surgical techniques can achieve a solid union, but the intertransverse posterolateral fusion (PLF) is the most widely used. However, complications can develop when the bone graft material used is insufficient to achieve the desired fusion. With its unique properties, nanOss Bioactive can be mixed with bone marrow aspirate (BMA) and other graft materials to obtain new bone growth during the healing process.
It is hypothesized that the use of nanOss Bioactive will result in fusion at 12 months, with CT evidence of bridging trabecular bone, less than 3mm of translational motion, and less than 5 degrees of angular motion. In addition, patients are expected to see an improvement in Oswestry Disability Index scores, VAS pain scores, and SF36 scores, while decreasing the use of pain medication, returning to work, and finding satisfaction in the results of their surgery.
Detailed Description
The post marketing clinical trial is designed to assess lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler in patients with degenerative disc disease (DDD) characterized by the inclusion and exclusion criteria listed below.
Patients for this study will be recruited from up to 10 clinical sites. It is estimated that 100 patients will be enrolled in the study. At least 10 investigators will participate in the study. Patients who meet the inclusion and exclusion criteria will be asked to sign the informed consent. Preoperatively, the patient will provide his /her medical history and complete self assessment forms. The investigator will perform a clinical evaluation.
Patients who meet the criteria for entrance into the study will undergo lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive in combination with local autograft and bone marrow aspirate (BMA). Anterior lumbar interbody fusion procedures are not allowed.
Following surgery, operative and discharge information will be collected. The patients will be evaluated at 6 weeks, 6 months and 12 months postoperatively. At each postoperative visit, the investigator will clinically evaluate the patient and the patient will complete self assessment documents, Oswestry Disability Index, Quality of Life questionnaires and a surgery satisfaction survey, e.g., very satisfied, satisfied, somewhat unsatisfied, or very unsatisfied with the surgery. Fusion status will be evaluated radiographically at each visit using plain films. CT scans at 12 months will be evaluated by an independent radiologist. Complication data will be recorded throughout the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Keywords
PLF, lumbar fusion, bone graft, biologics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
nanOss Bioactive Bone void filler
Arm Type
Other
Arm Description
Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
Intervention Type
Device
Intervention Name(s)
nanOss Bioactive Bone void filler
Intervention Description
Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
Intervention Type
Device
Intervention Name(s)
Interbody FCage
Intervention Description
Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
Primary Outcome Measure Information:
Title
Spinal fusion
Description
Bridging trabecular bone
Less than 3mm of translational motion
Less than 5mm of angular motion
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Improvement in Oswestry Disability Index score
Time Frame
12 months
Title
Improvement in VAS pain scores
Time Frame
12 months
Title
Improvement in Quality of Life scores
Time Frame
12 months
Title
Decrease in medication usage
Time Frame
12 months
Title
Patient returning to work
Time Frame
12 months
Title
Patient satisfaction (surgery satisfaction survey, e.g., very satisfied, satisfied, somewhat unsatisfied, or very unsatisfied with the surgery)
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patient can be included in the study if all of the following criteria are met;
is at least 18 years of age and skeletally mature
must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc disease (DDD) at one or two adjacent levels from L2-S1 requiring a fusion
must have completed a minimum of three months of unsuccessful conservative, non-operative care
must have discogenic back pain with or without leg pain
DDD must be confirmed by MRI or CT scans followed by discography (if necessary)
must score at least 40 points on the Oswestry Disability Index
must score at least a 4 on a 10 cm Visual Analog Scale for back pain
must be able to comply with the protocol"s follow-up schedule
must understand and sign the informed consent document
Exclusion Criteria:
The patient must not exhibit any of the following criteria;
symptomatic at more than two levels
previous fusion surgery at any lumbar level with or without instrumentation (prior discectomy, laminotomy, laminectomy or nucleolysis at the operative (involved) level > 6 months is permitted)
more than 50% spondylolisthesis
lumbar scoliosis greater than 11 degrees
osteoporosis*, osteopenia, osteomalacia, Paget"s disease or metabolic bone disease.
spinal tumors
active arachnoiditis Pioneer Surgical Technology Confidential nanOss Bioactive Post Marketing Clinical Study: March 11, 2010 Page 8
fractures of the epiphyseal plate or fractures for which stabilization of the fracture is not possible.
Impaired calcium metabolism
active infection or surgical site infection
rheumatoid arthritis or other autoimmune disease
chronic steroid use (used steroids for one month within the last 6 months) or any medical condition that requires treatment with drugs known to interfere with bone healing
systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis
morbid obesity defined as body mass index (BMI) >40 or a weight more than 100 lbs over ideal body weight
smokers unless the patient agrees to quit at least 2 weeks prior to and for the duration of the study, confirmed by a carboxyhemoglobin test prior to surgery
psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse
active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years
documented allergies to porcine collagen or titanium
pregnancy, or interested in becoming pregnant in the next four years
participation in another investigational study within 30 days *Osteoporosis will be assessed at the time of the preoperative evaluation based on the patient"s history, physical examination and review of the radiographic evaluations. All patients at risk for osteoporosis must obtain a DEXA scan of the spine and hip to determine if the patient has severe osteoporosis. The definition of a patient at risk used by the National Osteoporosis Foundation includes the following: i. Premature menopause (< 45 years) ii. Prolonged amenorrhea (> one year) iii. Maternal history of hip fracture iv. Primary hyperparathyroidism or hyperthyroidism v. Chronic renal failure vi. Previous fragility fractures, particularly of the hip, spine or wrist vii. Patients who have ever taken corticosteroids in doses >7.5 mg/day for one year or more. Patients will be excluded if their bone mineral density (BMD) in the spine or hip is more than 1.0 standard deviation (SD) below the mean of normal adults in the presence of one or more fragility fractures indicating severe osteoporosis. If severe osteoporosis is diagnosed, the patient must be excluded from the investigational study. If the patient has osteoporosis or osteopenia, they may be included in the study if he or she meets the rest of the inclusion and exclusion criteria.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mathew Songer, MD
Organizational Affiliation
Advanced Center for Orthopedics
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tower Orthopaedics & Neurosurgical Spine Institute
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
Scripps Memorial Hospital Neurosurgery
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Northwestern Medical Facility
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Advanced Center for Orthopedics
City
Marquette
State/Province
Michigan
ZIP/Postal Code
49855
Country
United States
Facility Name
St. Johns Spine and Pain Clinic
City
Springfield
State/Province
Missouri
ZIP/Postal Code
65804
Country
United States
Facility Name
Medical University of South Carolina Neurology
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Milwaukee Spinal Specialists
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53211
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effectiveness of Lumbar Fusion When NanOss Bioactive Is Used With Posterolateral Gutter Fusions
We'll reach out to this number within 24 hrs